A Single-Center Experience and Literature Review of Management Strategies for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients.
暂无分享,去创建一个
Nageena Khalid | Abdul Rafae | Patrick K. Campbell | Muhammad Abu Zar | A. Kamal | F. Anwer | T. Zangeneh | A. Mushtaq | A. Majeed | Ahmad Iftikhar | M. Lakhani | Marti M Larriva | Mustafa Nadeem Malik
[1] J. Reguła,et al. Guidelines for Clostridium difficile infection in adults , 2020, Przeglad gastroenterologiczny.
[2] K. Carroll,et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Scott E. Smith,et al. Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients , 2017, Pharmacotherapy.
[4] E. Robilotti,et al. Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation , 2017, The Journal of infectious diseases.
[5] C. Flowers,et al. Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study , 2017, Infection Control & Hospital Epidemiology.
[6] D. Paterson,et al. Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study , 2017, Open forum infectious diseases.
[7] E. Burd,et al. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period , 2017, Transplant infectious disease : an official journal of the Transplantation Society.
[8] K. Marr,et al. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single‐center study in Québec, Canada , 2017, Transplant infectious disease : an official journal of the Transplantation Society.
[9] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection , 2017, The New England journal of medicine.
[10] J. Cobo,et al. Clostridium difficile Infection in Special High-Risk Populations , 2016, Infectious Diseases and Therapy.
[11] H. Nakasone,et al. Significance of a positive Clostridium difficile toxin test after hematopoietic stem cell transplantation , 2016, Clinical transplantation.
[12] A. Wald,et al. Evaluating risk factors for Clostridiumdifficile infection in adult and pediatric hematopoietic cell transplant recipients , 2015, Antimicrobial Resistance and Infection Control.
[13] P. Ramírez,et al. Clostridium difficile infection in Chilean patients submitted to hematopoietic stem cell transplantation , 2015, Revista brasileira de hematologia e hemoterapia.
[14] J. Bartlett,et al. Impact of Toxigenic Clostridium difficile Colonization on the Risk of Subsequent C. difficile Infection in Intensive Care Unit Patients , 2015, Infection Control & Hospital Epidemiology.
[15] Lanjuan Li,et al. Risk factors, outcomes and epidemiology associated with Clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China. , 2015, Journal of medical microbiology.
[16] J. Meek,et al. Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.
[17] A. Kaltsas,et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] N. Flomenberg,et al. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] J. N. de Almeida,et al. INCIDENCE OF DIARRHEA BY Clostridium difficile IN HEMATOLOGIC PATIENTS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS: RISK FACTORS FOR SEVERE FORMS AND DEATH , 2014, Revista do Instituto de Medicina Tropical de Sao Paulo.
[20] M. von Bergwelt-Baildon,et al. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] R. Lynfield,et al. Multistate point-prevalence survey of health care-associated infections. , 2014, The New England journal of medicine.
[22] Yeon Joo Lee,et al. Early Clostridium difficile Infection during Allogeneic Hematopoietic Stem Cell Transplantation , 2014, PloS one.
[23] M. P. Bauer,et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] E. Anaissie,et al. Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.
[25] C. Huff,et al. Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] Mark A. Miller,et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy , 2013, BMC Infectious Diseases.
[27] J. Mehta,et al. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] R. Porcher,et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] C. Luxemburger,et al. Clostridium difficile: development of a novel candidate vaccine. , 2012, Vaccine.
[30] C. Huff,et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] T. Marbury,et al. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. , 2012, Vaccine.
[32] T. Wilt,et al. Comparative Effectiveness of Clostridium difficile Treatments , 2011, Annals of Internal Medicine.
[33] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[34] E. Kuijper,et al. Clostridium difficile infection in Europe: a hospital-based survey , 2011, The Lancet.
[35] N. Safdar,et al. Prevention of Endemic Healthcare-Associated Clostridium difficile Infection: Reviewing the Evidence , 2010, The American Journal of Gastroenterology.
[36] J. Dipersio,et al. Clostridium difficile‐associated disease in allogeneic hematopoietic stem‐cell transplant recipients: risk associations, protective associations, and outcomes , 2010, Clinical transplantation.
[37] Mark H. Wilcox,et al. Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.
[38] C. Kelly,et al. Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.
[39] L. Gentry,et al. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. , 2008, The Journal of hospital infection.
[40] Melinda B Davis,et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] J. Dipersio,et al. Severity of Clostridium difficile–Associated Disease (CDAD) in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD Severity Grading System , 2007, Infection Control & Hospital Epidemiology.
[42] M. Restrepo,et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma , 2006, Bone Marrow Transplantation.
[43] T. Monath,et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. , 2005, Gastroenterology.
[44] C. Kelly,et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.
[45] D. Milligan,et al. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality , 2000, Bone Marrow Transplantation.
[46] C. Kelly,et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.
[47] J. Clive,et al. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.
[48] M. Samore,et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea , 1998, The Lancet.
[49] C. Surawicz,et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] M. Samore,et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] K. Carroll,et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] G. Alangaden,et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation , 2011, Clinical transplantation.
[53] Guang-xi Li,et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .
[54] S. Raza,et al. Clostridium difficile infection following chemotherapy. , 2010, Recent patents on anti-infective drug discovery.
[55] M. Kalaycio,et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients , 2000, Bone Marrow Transplantation.